Cologuard from Exact Sciences Corp. - stool DNA kit reshapes home screening

Reviewed: ad hoc news Lifestyle & Consumer desk. Edited and checked on 2026-06-26, 06:38. Details in the imprint.

Cologuard from Exact Sciences Corp. sits on the bathroom floor, a white plastic kit that turns an awkward stool sample into a lab-grade colorectal cancer screen. You hear the snap of the lid, seal the box, and a courier takes your sample away instead of a hospital nurse.

How Cologuard works

Cologuard is a prescription stool DNA test that looks for blood and abnormal DNA shed by colorectal tumors or advanced polyps in a single sample collected at home. It is cleared for average-risk adults starting at 45 years and is intended as a non-invasive screening option.

The kit arrives by mail, includes a collection container and preservative solution, and goes back to a central lab in prepaid packaging. Patients do not need bowel prep, diet restrictions, or sedation, which lowers the psychological barrier compared with a colonoscopy for many people.

What patients experience

In practice, patients place the collection bracket on the toilet, do their business, then pour a stabilizing liquid over the stool before closing the lid. The plastic feels robust rather than flimsy, which reassures people who worry about leaks during shipping.

Gastroenterologist Thomas Imperiale, who has worked with Exact Sciences on trial data in the past, has described stool DNA tests as a way to reach patients who avoid invasive procedures and might otherwise skip screening entirely. That is exactly the group Cologuard targets in primary care practices and telehealth programs.

Clinical performance and limits

Cologuard is based on a pivotal trial that showed high sensitivity for colorectal cancer and meaningful detection of advanced precancerous lesions, but with a lower specificity than traditional fecal immunochemical tests. That means more false positives and follow-up colonoscopies when the stool test flags an issue.

Guidelines generally recommend repeating Cologuard every three years for people who stay at average risk and have a negative result. A positive result still sends the patient to diagnostic colonoscopy, so the product complements rather than replaces endoscopy capacity in healthcare systems.

Pricing, access and adoption

In the United States, Cologuard is reimbursed by many commercial insurers and by public payers such as Medicare for eligible age groups, which has been central to its adoption curve. The list price is significantly higher than simple stool blood tests but lower than a full colonoscopy episode when anesthesia and facility fees are included.

Exact Sciences has built a direct-to-consumer style presence around Cologuard with advertising that encourages people to talk to their doctor about non-invasive screening. At the same time, the company leans on primary care workflows and electronic health record integrations so clinicians can order the test and track results without extra paperwork.

Context and stock reference

Overall, Cologuard remains the flagship stool DNA screening product in the Exact Sciences portfolio and a pillar of its recurring revenue model. Exact Sciences shares (ISIN US30063P1057) trade on Nasdaq in US dollars, and the Cologuard testing volume is one of the metrics professional investors watch closely.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.